|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Indian Council of Medical Research |
|---|---|
| Collaborator: |
Department of Biotechnology-DBT India |
| Information provided by: | Indian Council of Medical Research |
| ClinicalTrials.gov Identifier: | NCT00507000 |
Purpose
Tuberculosis and vitamin D deficiency are important public health problems in India. Before the advent of effective antitubercular therapy, patients with tuberculosis were advised treatment and rest at sanatorium where sunshine was available in plenty. There have been reports associating vitamin D deficiency with tuberculosis in terms of incidence and beneficial response following addition of vitamin D to antitubercular therapy. Sputum AFB conversion rate is higher in patients with tuberculosis supplemented with vitamin D. The present study would systematically assess role of adjunct vitamin D therapy (cholecalciferol) in patients with pulmonary tuberculosis.
| Condition | Intervention | Phase |
|---|---|---|
|
Tuberculosis |
Drug: Cholecalciferol Drug: Lactose granules |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Role of Oral Vitamin D as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters. (Double-blind, Randomized, Placebo-Controlled, Clinical Trial) |
| Estimated Enrollment: | 150 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | September 2010 |
| Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
A, Cholecalciferol: Active Comparator
A Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
|
Drug: Cholecalciferol
Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Choelcalciferol
|
|
Vitamin D and Tuberculosis: Placebo Comparator
B, Lactose
|
Drug: Lactose granules
Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
|
Tuberculosis and vitamin D deficiency are important public health problems in India. In recently published studies from our center, up to 90% of the apparently healthy subjects in Delhi were classified either as as vitamin D insufficient or deficient by using serum 25(OH)D cut off levels of 20 ng/ml and 32 ng/ml respectively. Before the advent of effective antitubercular therapy, patients with tuberculosis were advised treatment and rest at sanatorium where sunshine was available in plenty. In the western literature, there have been reports associating vitamin D deficiency with tuberculosis in terms of incidence and beneficial response following addition of vitamin D to antitubercular therapy. A few pilot studies have shown that sputum conversion rate is higher in patients with tuberculosis supplemented with vitamin D.
In the above context the mechanisms linking vitamin D deficiency and its effect on tuberculosis are currently under investigation. In order to understand the link two types of studies have been conducted (a) clinical studies associating vitamin D deficiency and tuberculosis and (b) in-vitro assessment of molecular immune changes related to vitamin D exposure. With the currently available knowledge, the linkage between the two disorders is being explained by the broad role of vitamin D deficiency in modulation of cell-mediated immunity.
Patients with military tuberculosis are characterized by decreased levels of Th1 cytokines and increased levels of IL-10 compared with the healthy infected and noninfected controls. Current literature suggests that long-term control of M. tuberculosis infection is associated with elevated Th1 responses and concomitant inhibition of the Th2 response
Peripheral blood mononuclear cells have been shown to express vitamin D receptors. Incubation of macro¬phages with physio¬logical concentration of 1,25 (OH)D [10-9M] results in inhibition of intracellular growth of Mycobacterium tuberculosis. 1,25-dihydroxycholecalciferol, has significant immunomodulatory effects leading to (a) shift in cytokine profile of T-helper (Th1 to Th2) and (b) reduced antigen presentation, reduced production of Th1-promoting cytokines, reduced expression of co-stimulatory molecules in the antigen-presenting cell. In addition, it was demonstrated that the addition of vitamin D3 derivatives inhibits the differentiation of IFN-gamma-producing Th1 cells while it augments the differentiation of IL-4- or IL-10-producing Th2 cells.
There are no systematic data from our country assessing association between vitamin D deficiency and tuberculosis and the possible role of vitamin D related modulation in the tuberculosis specific cellular immune response. The present study has been planned with the following hypothesis
Hypothesis: Patients with pulmonary tuberculosis and vitamin D deficiency when treated with vitamin and antitubercular therapy are likely to show early sputum conversion and immune response favoring resolution of tuberculosis
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Ravinder Goswami, MD, DM | 26588500 ext 4272 | gosravinder@hotmail.com |
| Contact: SK Sharma, MD, PhD | 26588500 ext 4415 | sksharma@aiims.ac.in |
| India, New Delhi | |
| Depratment of Medicine, All India Institute of Medical sciences, | Recruiting |
| Delhi, New Delhi, India, 110029 | |
| Contact: SK Sharma, MD, PhD 26588500 ext 4415 | |
| Principal Investigator: | Ravinder Goswami, MD, DM | Associate Professor, Depratment of Endocrinology and Metabolism, All India Institute of Medical Sciences, New delhi 110029 |
| Principal Investigator: | SK Sharma, MD, PHD | Head, Depratment of Medicine, All India Institute of Medical Sciences, New Delhi 110029 |
| Principal Investigator: | DK Mitra, MBBS, PhD | Associate professor, Department of Transplant immunology and immunogenetics, All India Institute of Medicasl Sciences, New delhi 110029, India |
| Principal Investigator: | Urvashi B Singh, MD, PhD | Assistant Professor, Deprtament of Microbiology, All India Institute of Medical Sciences, new delhi 110029 |
| Principal Investigator: | Nandita Gupta, PhD | Additional Porfessor, Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi 110029, India |
More Information
| Responsible Party: | All India Institute of Medical sciences, New delhi ( Depratment of Biotechnology (Dr R Goswami, Principal Investigator) ) |
| Study ID Numbers: | BT/pr7898/Med/14/1179/2006 |
| Study First Received: | July 23, 2007 |
| Last Updated: | July 14, 2009 |
| ClinicalTrials.gov Identifier: | NCT00507000 History of Changes |
| Health Authority: | India: Institutional Review Board |
|
Bacterial Infections Cholecalciferol Growth Substances Physiological Effects of Drugs Ergocalciferols Bone Density Conservation Agents Pharmacologic Actions Actinomycetales Infections Gram-Positive Bacterial Infections |
Vitamin D Respiratory Tract Diseases Respiratory Tract Infections Lung Diseases Vitamins Tuberculosis, Pulmonary Mycobacterium Infections Tuberculosis Micronutrients |